This recombinant monoclonal antibody is designed as a research-grade biosimilar to Tremelimumab, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a critical immune checkpoint receptor expressed on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. By delivering inhibitory signals, CTLA4 maintains immune homeostasis and prevents excessive T-cell responses. Dysregulation of CTLA4-mediated immune suppression is implicated in various cancers, where tumor cells exploit this checkpoint to evade immune surveillance, making it a significant target in immuno-oncology research.
Tremelimumab is a fully humanized IgG2 monoclonal antibody that blocks CTLA4, thereby enhancing anti-tumor immune responses through T-cell activation. This biosimilar antibody serves as a valuable research tool for investigating CTLA4 biology, immune checkpoint mechanisms, and T-cell regulation in various disease models. It enables studies exploring combination immunotherapy strategies, tumor microenvironment dynamics, and immune evasion mechanisms in cancer research.
Email: support@cusabio.com
Distributors Worldwide